Stealth BioTherapeutics Corp.
Stealth BioTherapeutics Corp. is an innovative biopharmaceutical company developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases.
Stealth BioTherapeutics' mission is to lead the development of mitochondrial medicine to improve the lives of patients with diseases involving mitochondrial dysfunction, an area of high unmet clinical need.
Location of Key Operations
Deloitte Touche Tohmatsu CPA LLP
IPO (February 15, 2019)
Newton, Massachusetts, USA
Janhavi Mohite, Stern IR